DOI: https://doi.org/10.22141/2224-0721.15.3.2019.172107

Activation of intracellular enzyme systems under the influence of pathogenetic factors of oncogenesis in patients with type 2 diabetes mellitus

T.S. Vatseba

Abstract


Background. It is proved that patients with diabetes mellitus (DM) have an increased risk of cancer. The main factors of oncogenesis in DM are obesity, cytokine imbalance, hyperinsulinemia (HI), hyperglycemia. These disorders cause dysfunction of the intracellular regulatory signaling pathways, the main of which is PI3K/Akt/mTOR. The purpose of the work was to study the role of phosphorylated Akt-protein kinase (phospho-Akt) in the oncogenesis processes in patients with type 2 DM. Materials and methods. Seventy-five people were examined. Patients were divided into groups: І — healthy, ІІ — persons with DM type 2, ІІІ — patients with cancer, IV — patients with cancer and DM type 2. Patients with breast, endometrial, pancreatic and intestinal cancer were included in the study. The levels of insulin, insulin-like growth factor 1 (IGF-1) and phospho-Akt were determined. Results. Patients of groups II and IV had a decompensated DM with HbA1c level > 8.0 %. Reliable HI was found in patients with DM in groups II and IV (p < 0.05), IGF-1 level was increased in all study groups (p < 0.05). Levels of phospho-Akt in patients from groups II and III were elevated (p < 0.05) and in group IV — reduced (p < 0.05). In the third group, HI in patients with breast, endometrial and intestinal cancer (p < 0.05) was detected, as well as elevation of IGF-1 regardless of localization (p < 0.05). In group IV, increased content of insulin and IGF-1 were detected in patients with breast and endometrial cancer (p < 0.05). In women from group III with breast and endometrial cancer, the level of IGF-1 was higher than that of group IV (p < 0.05). In patients treated with metformin monotherapy, phospho-Akt level was significantly lower (p < 0.05). There was a direct correlation between phospho-Akt and IGF-1 in patients of group II (r = 0.50; p < 0.05) and between phospho-Akt and insulin in group III (r = 0.45; p < 0.05). Conclusions. HI and IGF-1 are common pathogenetic factors of type 2 DM and cancer. The elevated level of phospho-Akt can serve as a laboratory indicator of cancer risk in healthy individuals. The combination of type 2 DM and cancer causes a decrease in phospho-Akt due to the competitive interaction of intracellular signaling pathways. Metformin therapy helps to reduce phospho-Akt level and can be considered as one of the ways to prevent cancer.


Keywords


diabetes mellitus; hyperinsulinemia; risk of cancer; signaling pathways

References


Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care. 2015 Feb;38(2):264-70. doi: 10.2337/dc14-1996.

Oberaigner W, Ebenbichler C, Oberaigner K, Juchum M, Schönherr HR, Lechleitner M. Increased cancer incidence risk in type 2 diabetes mellitus: results from a cohort study in Tyrol/Austria. BMC Public Health. 2014 Oct 10;14:1058. doi: 10.1186/1471-2458-14-1058.

Vatseba TS, Sokolova LK. Pathogenegenetic mechanisms of oncogenesis in diabetes mellitus and analysis of cancer incidence in patients with diabetes mellitus in the Precarpathian region. Endokrynologia. 2018;2(23):128-136. (in Ukrainian).

Jian Gang P, Mo L, Lu Y, Runqi L, Xing Z. Diabetes mellitus and the risk of prostate cancer: an update and cumulative meta-analysis. Endocr Res. 2015;40(1):54-61. doi: 10.3109/07435800.2014.934961.

Ray A, Fornsaglio J, Dogan S, Hedau S, Naik D, De A. Gynaecological cancers and leptin: A focus on the endometrium and ovary. Facts Views Vis Obgyn. 2018 Mar;10(1):5-18.

Li ZJ, Yang XL, Yao Y, Han WQ, Li BO. Circulating adiponectin levels and risk of endometrial cancer: Systematic review and meta analysis. Exp Ther Med. 2016 Jun;11(6):2305-2313. doi: 10.3892/etm.2016.3251.

Sun XF, Shao YB, Liu MG, et al. High-concentration glucose enhances invasion in invasive ductal breast carcinoma by promoting Glut1/MMP2/MMP9 axis expression. Oncol Lett. 2017 May;13(5):2989-2995. doi: 10.3892/ol.2017.5843.

Chen L, Chen R, Wang H, Liang F. Mechanisms linking inflammation to insulin resistance. Int J Endocrinol. 2015;2015:508409. doi: 10.1155/2015/508409.

Jiménez СG, María Salmerón G, Calvo AC, et al. From obesity to diabetes and cancer: epidemiological links and role of therapies. Br J Cancer. 2016 Mar 29;114(7):716-22. doi: 10.1038/bjc.2016.37.

Pushkarev VM, Sokolova LK, Pushkarev VV, Tronko MD. Biochemical mechanisms connecting diabetes and cancer. Effects of methormine. Endokrynologia. 2018;23(2):167-180. (in Ukrainian).

Gristina V, Cupri MG, Torchio M, Mezzogori C, Cacciabue L, Danova M. Diabetes and cancer: А critical appraisal of the pathogenetic and therapeutic links. Biomed Rep. 2015 Mar;3(2):131-136. doi: 10.3892/br.2014.399.

Semple RK. EJE PRIZE 2015: How does insulin resistance arise, and how does it cause disease? Eur J Endocrinol. 2016 May;174(5):R209-23. doi: 10.1530/EJE-15-1131.

Pushkarev VM, Sokolova LK, Pushkarev VV, Tronko MD. The role of AMPK and mTOR in the development of insulin resistance and type 2 diabetes. The mechanism of metformin action (literature review). Problemi endokrinnoi patologii. 2016;(57):77-90. (in Russsian).

Farese RV, Sajan MP. Metabolic functions of atypical protein kinase C: "good" and "bad" as defined by nutritional status. Am J Physiol Endocrinol Metab. 2010 Mar;298(3):E385-94. doi: 10.1152/ajpendo.00608.2009.

Ong PS, Wang LZ, Dai X, Tseng SH, Loo SJ, Sethi G. Judicious toggling of mTOR activity to combat insulin resistance and cancer: current evidence and perspectives. Front Pharmacol. 2016 Oct 25;7:395. doi: 10.3389/fphar.2016.00395.

Anisimov VN, Bartke A. The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer. Crit Rev Oncol Hematol. 2013 Sep;87(3):201-23. doi: 10.1016/j.critrevonc.2013.01.005.

Andersen DK, Korc M, Petersen GM, et al. Pancreatogenic diabetes and pancreatic cancer. Diabetes. 2017 May;66(5):1103-1110. doi: 10.2337/db16-1477.

Mengqiu SA, Bode M, Dong Z, Lee MH. AKT as a therapeutic target for cancer. Cancer Res. 2019 Mar 15;79(6):1019-1031. doi: 10.1158/0008-5472.CAN-18-2738.

Mundi PS, Sachdev J, McCourt C, Kalinsky K. AKT in cancer: new molecular insights and advances in drug development. Br J Clin Pharmacol. 2016 Oct;82(4):943-56. doi: 10.1111/bcp.13021.






Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2019

 

   Seo анализ сайта